MINI Act

Both the US House and US Senate have introduced bipartisan legislation to maintain incentives for investment in cardiovascular research and development. The Maintaining Investments in New Innovation Act, commonly referred to as The MINI Act, promotes and supports medical innovation in the United States by extending the amount of time certain “genetically targeted” therapies are on market before they are subject to regulations signed into law by the Inflation Reduction Act.

Resources

Featured

Genetically Targeted Technologies and the MINI Act

PACH One-Pager

[Webinar] Genetically Targeted Technologies and the MINI Act

PACH Webinar

A MINI Act Could Be Big for Heart Patients

PACH Video

Genetically Targeted Technologies: A Big Win for Heart Patients

PACH Infographic

A “MINI” Act Could Be Big for Patients

Health Policy Today Blog

Overview and Outlook for RNA-Based Therapies

Avalere Study

IRA Drug Price Negotiation Impact on Cardiovascular Drugs

Avalere Study

Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the US Inflation Reduction Act

Article Published on the Journal of Medical Economics

The MINI Act & Genetically Targeted Technologies

Genetically targeted technologies promise a new way to deliver medication and help heart patients manage their conditions. The MINI Act would allow more time for research, investment and infrastructure for GTTs.

Learn more

Take Action

Innovation expands patients’ treatment options, creating greater opportunity for improved quality of life. The MINI Act (S.476 | H.R.5547) would incentivize continued innovation. Ask your legislator to support it.

Contact your legislator now